BIVV 009

Drug Profile

BIVV 009

Alternative Names: BIVV-009; TNT-009

Latest Information Update: 04 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator True North Therapeutics
  • Developer Bioverativ
  • Class Antianaemics; Monoclonal antibodies
  • Mechanism of Action Complement C1s inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Autoimmune haemolytic anaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Autoimmune haemolytic anaemia; Bullous pemphigoid; Renal transplant rejection

Most Recent Events

  • 02 Aug 2017 Bioverativ plans a phase III trial for Autoimmune haemolytic anaemia in 2017
  • 28 Jun 2017 True North Therapeutics has been acquired and merged into Bioverativ
  • 23 May 2017 Preclinical trials in Autoimmune haemolytic anaemia in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top